Auk, further to your great research.
- The Anagrelide metabolite (3-hydroxy-anagrelide) is likely to be the main contributor to the negative cardiovascular effects of the drug. (TGA PAR ref)
- (Suda update 21 Feb 2019)
No liver metabolism = no metabolite = no cardio vascular impacts
All good really.
Now some good news that affects the share price (positively) would be appreciated Carter.
Auk, further to your great research. The Anagrelide metabolite...
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ALA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
13.5¢ |
Change
-0.015(10.0%) |
Mkt cap ! $141.9M | |||
| Open | High | Low | Value | Volume |
| 15.0¢ | 15.0¢ | 13.5¢ | $142.4K | 1.003M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 250803 | 13.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 14.0¢ | 74996 | 3 |
View Market Depth
| Last trade - 16.10pm 08/08/2024 (20 minute delay) ? |
| ALA (ASX) Chart |